Elevated plasma ceramides in depression

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 23, Issue 2, 2011, Pages 215-218

  Gracia Garcia, Patricia ^a   Rao, Vani ^b   Haughey, Norman J ^b   Banduru, Veera Venkata Ratnam ^b   Smith, Gwenn ^b   Rosenberg, Paul B ^b   Lobo, Antonio ^a   Lyketsos, Constantine G ^b   Mielke, Michelle M ^b  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CERAMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RATING SCALE; BLOOD;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CERAMIDES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE;

EID: 85045312625     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/jnp.23.2.jnp215     Document Type: Article

References (15)

1. Schildkraut JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122:509-522
2. Claus RA, Dorer MJ, Bunck AC, et al: Inhibition of sphingomyelin hydrolysis: targeting the lipid-mediator ceramide as a key regulator of cellular fate. Curr Med Chem 2009; 16:1978-2000
3. Riddle EL, Rau KS, Topham MK, et al: Ceramide-induced alterations in dopamine-transporter function. Eur J Pharmacol 2003; 458:31-36
4. Jafurulla M, Pucadyil TJ, Chattopadhyay A: Effect of sphingomyelinase treatment on ligand binding activity of human serotonin1A receptors. Biochim Biophys Acta 2008; 1778:2022-2025
5. Kornhuber J, Medlin A, Bleich S, et al: High activity of acid sphingomyelinase in major depression. J Neural Transm 2005; 112:1583-1590
6. Lyketsos CG, Steinberg M, Tschanz JT, et al: Mental and behavioral disturbances in dementia: findings from The Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157:708-714
7. Cutler RG, Kelly J, Storie K, et al: Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A 2004; 101:2070-2075
8. Mielke MM, Bandaru VV, Haughey NJ, et al: Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 2010; 31:17-24
9. Puglielli L, Ellis BC, Saunders AJ, et al: Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 2003; 278:19777-19783
10. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414
11. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group Under the Auspices of the Department of Health and Human Services Taskforce on Alzheimer's Disease. Neurology 1984; 34:939-944
12. Bandaru VV, McArthur JC, Sacktor N, et al: Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology 2007; 68:1481-1487
13. Kornhuber J, Reichel M, Tripal P, et al: The role of ceramide in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 2009; 259(suppl 2):S199-S204
14. Shimizu M, Tada E, Makiyama T, et al: Effects of ceramide, ceramidase inhibition, and expression of ceramide kinase on cytosolic phospholipase A2alpha: additional role of ceramide- 1-phosphate in phosphorylation and Ca2+ signaling. Cell Signal 2009; 21:440-447
15. Noponen M, Sanfilipo M, Samanich K, et al: Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry 1993; 34:641-649